A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Overview of attention for article published in Journal of Hematology & Oncology, April 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 1 X user

f1000: 1 research highlight platform

Readers on

mendeley: 37 Mendeley

Summary X Research highlights

So far, Altmetric has seen 1 X post from an account with 968 followers.

#endlymphoma Phase II study on gemcitabine/romidepsin (GEMRO regimen) in RR-peripheral T-cell #lymphoma https://t.co/ecpT5G7Ftp

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.